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by binding to a novel allosteric site within LFA-1 [5].
Another beneficial effect of statins may be the switch from Th1
to Th2 cytokines, as demonstrated for atorvastatine in a
murine model [6]. Statins reduce CD40 expression in atheroma-
associated cells in atherosclerotic lesions in situ in treated patients
[7]. Fluvastatin has recently been shown to induce apoptosis
in vitro in RA synoviocytes through a mitochondrial and caspase-
3-dependent pathway and by inhibition of the geranylgeranyl
pathway [8]. One may speculate that some of these previously
proven mechanisms of action may be of relevance in the
presented case.
Cholesterol crystalloids may appear as negatively birefringent,
large, flat rectangular plates with notched corners, ranging from 8
to 100m, consisting of monohydrate cholesterol. These are
thermodynamically stable and not easily cleared. This case
lends support to the hypothesis that locoregional monohydrate
cholesterol production or one of the aforementioned mechanisms
(suppression of class II MHC or Th1–Th2 switch) play a
pivotal role in the aetiopathogenesis of cholesterol synovitis, as
cholesterol synovitis can be inhibited by atorvastatine in humans.
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Unilateral polymyalgia rheumatica with controlateral
sympathetic dystrophy syndrome. A case of asymmetrical
involvement due to pre-existing peripheral palsy
SIR, We describe the case of a man with pre-existing peripheral
palsy who developed polymyalgia rheumatica (PMR); he was
spared arthritis in the affected limb but experienced reflex
sympathetic dystrophy syndrome (rSDS) in the paretic arm.
A 72-year-old man was admitted to our hospital because of
nocturnal pain in his right shoulder and the pelvic girdle, with
long-lasting morning stiffness, mild fever and weight loss. The
pain in his buttocks and thighs was so severe that it limited his
ability to stand and walk. His knee reflex responses were
symmetrically reduced, and he was admitted to the Neurological
Department with suspected paraparesis. The shoulder pain was
not taken into account because the patient reported a diagnosis of
rotator cuff tendinitis that had been made some days before by
another physician.
The patient’s history included left axilla irradiation performed
30 yrs ago because of a ‘lymphogranuloma’, which led to brachial
plexus damage and peripheral palsy in the arm; the lymphoma did
not relapse and the patient did not receive any other treatment.
TABLE 1. Time points of shoulder punctures, and correlation of total intra-articular cholesterol with three therapeutic interventions (bold)
T (weeks) 0 8 12 16 20 28
Therapeutic measures
SSZ 2 g/dy 1 g/dy 1 g/dy 1 g/dy stop stop
MTX starta cont cont cont cont cont
10mg sc 10mg sc 10mg sc 10mg sc 10mg sc 10mg sc
MPA ia 0 0 1xb 0 0 0
40mgb
Atorvastatine 0 0 0 startc continue cont
20mg/dy 20mg/dy 20mg/dy
Shoulder puncture results
Volume SF (ml) 80 50 30 130 12 0
Leucocyte count (109/l) 2.6 5.3 5.4 5.0 2.2 0
Cholesterol (mM) 7.8 7.4 7.8 12.9 5.9 0
Outcome parameters
SF cholesterol (mol) 624 370 234 1677 70 0
DAS28 5.1 3.3 3.3 3.1 2.7 1.9
aStarting and subsequently continuing methotrexate (MTX), bintra-articular methylprednisolone acetate (MPA ia) injection, cstarting and subsequently
continuing atorvastatine treatment.
Disease activity of RA is measured according validated scoring method applying 28 joint counts; interpretation: high disease activity when DAS28> 5.1;
low activity when DAS28< 3.2.
g/dy¼ grams per day; cont¼ continue; sc¼ subcutaneous; ia¼ intra-articular; SF¼ synovial fluid.
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The motor impairment in his left arm was nearly complete,
although some degree of useless movement persisted. The
sympathetic fibres were relatively spared, allowing the presence
of sweat and vasomotor reflexes, and the arm retained some
tactile, thermal and noxious sensitivity.
Neurological examination did not reveal any other gross
abnormalities, and the administration of analgesics allowed the
patient to stand and walk. He had mild fever (37.58), an
erythrocyte sedimentation rate (ESR) of 120mm/h, and mild,
normochromic and normocytic anaemia. He was subsequently
referred to our department because of suspected PMR.
Rheumatoid factor (RF), anti-nuclear antibodies (ANA) and
anti-neutrophil cytoplasm antibodies (ANCA) were negative, and
muscle enzymes were normal. The patient denied headache or
visual abnormalities, and the results of a temporal biopsy were
normal. A scan revealed increased Tc99 uptake in the right but not
the left shoulder (Fig. 1).
The prednisolone (25mg/day) led to the prompt disappearance
of the right shoulder and pelvic girdle pain, the normalization of body
temperature and ESR (25mm/h). Tapering was started after 1 month.
One month later, left hand was affected by a painful pitting
swelling, accompanied by a glossy and bluish skin, continuous
sweating and thermal disturbances. Radiology showed spotty
atrophy and the Tc99 scan, which had previously been symmetrical
and normal at the hands, showed increased vascular flow and
bone activity in the affected area. Rx pattern was consistent with
the diagnosis of rSDS. Biphosphonate therapy with clodronate
was started, and 1 month later led to improved symptoms and
reduced oedema.
PMR is an inflammatory disease that variably involves the
upper and lower girdle, but has a well-defined symmetry [1].
To the best of our knowledge, there is only one previously
published report of a case of PMR leading to established central
hemiparesis [2] with the sparing of the affected site.
In our case, the patient’s complaint and the scintigraphy results
explain the unilateral involvement of the upper girdle. The
presence of brachial palsy may have had a protective effect on
the appearance of arthritis in the affected limb, but the altered
neural control induced rSDS.
It has been reported that central [3] or peripheral denervation
[4] can protect against rheumatoid artheritis (RA). Pre-existing
denervation can avoid the emergence of arthritis and erosions in
the paretic limbs and, when the neural defect occurs after
established RA, it can also ameliorate synovitis [5], and even
induce erosion recovery [6]; the more severe the neurological
damage, the more pronounced the sparing effect.
FIG. 1. (A) Bone scintigraphy showing the main uptake in the right shoulder and (B) the Tc99 scan of the hands showed increased
vascular flow and bone activity of the affected area. From upper left to lower: increased vascular flow; blood pool; increased uptake at
steady state; persistence of inflammation of right shoulder.
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A number of previous reports [3, 4, 7] suggested that the
lack of mobilization and/or reduced vascular supply in the
denervated limb may explain this sparing effect, but it is
currently believed that the functional or anatomical reduction in
nervous fibres is the common, necessary and sufficient underlying
reason.
The nervous system plays an active role in inflammation, which
it can induce in experimental and human models (neurogenic
inflammation) by producing and releasing neuropeptides.
Neurogenic inflammation may amplify immune complex-
dependent inflammation, and a number of observations suggest
that the nervous system plays a role in generating and maintaining
arthritis [8]. Various neuropeptides can control the milieu by
interacting with the surrounding and circulating cells, regulating
the activity of the immune system (and its dependent production
of cytokines) as well as vascular tone [9].
rSDS is a pathological condition due to hyperactivity of the
autonomic nervous system; it is frequently triggered by noxious
stimuli or interference with central nervous outflow (strokes,
the use of anti-convulsants), and mechanisms of neurogenic switch
are involved in its appearance [7]. There is only one previously
published case of rSDS complicating PMR [10].
Sympathetic fibres are characterized by low-grade activation,
which is increased by activity in the primary afferent nociceptive
nerves, and some conditions due to an abnormal increase in
this activity (frequently triggered by noxious stimuli or CNS
interference due to ischaemic or pharmacological insults) can lead
to rSDS.
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Traditional cardiovascular risk factors in primary Sjo¨gren’s
syndrome—role of dyslipidaemia
SIR, The development of precocious atherosclerosis with
its consequences on cardiovascular (CV) mortality in some
rheumatic diseases, such as rheumatoid arthritis (RA) and
systemic lupus erythematosus (SLE), is well established [1].
Although there is evidence that both the disorders represent an
independent risk factor for CV disease, it is thought that
traditional risk factors, including dyslipidaemia, also may
contribute to accelerated atherosclerosis in these patients [1].
Primary Sjo¨gren’s syndrome (SS) is a systemic autoimmune
disorder characterized by chronic inflammation of exocrine
glands. Although it is not clear if an increase in CV death
occurs in this disorder [2], SS may represent an interesting
model to study the factors involved in early development of
atherosclerosis. It shares, indeed, a number of clinical and
serological features typical of both RA and SLE, but, unlike
these disorders, it does not often need treatments, which may
influence the CV risk profile of these subjects, because
of a frequently indolent course of the disease.
Lodde et al. [3] recently described lower levels of total
and high-density lipoprotein (HDL) cholesterol in patients
with primary SS with respect to those of xerostomic
control subjects. This datum confirms, at least in part,
the results of our study showing reduced levels of HDL, but
not total, cholesterol in 37 women with primary SS compared
with 35 age-matched control females ( [4] and Table 1). Similar to
the Lodde’s study, we failed to find differences in low-density
lipoprotein (LDL) cholesterol, triglycerides, non-HDL choles-
terol, total/HDL and LDL/HDL cholesterol ratio and high-risk
HDL cholesterol levels between patient and control groups (data
not shown). It is intriguing, however, that an association between
anti-SSA/SSB antibodies and altered cholesterol levels was found
in the Lodde’s study. We performed, therefore, a post hoc analysis
of lipid levels in our series by selecting the SS patient subset
with evidence of circulating anti-SSA (71% also anti-SSBþ).
As shown in Table 1, the patients with anti-SSA/SSB antibodies
had lower levels of total and HDL cholesterol and increased
high-risk HDL cholesterol levels than control subjects, thereby
confirming an association between dyslipidaemia and SS-specific
autoantibodies.
The finding of dyslipidaemia, and in particular low level
of HDL cholesterol in SS, is of great interest, but raises some
critical questions. As reminded by Lodde, similar findings have
been found in both RA and SLE and it is conceivable that they
may be the results of chronic inflammation. However, we do
not believe that the presence of specific autoantibodies, such
as anti-SSA/SSB, may reflect SS disease activity, as Lodde
states. Unlike RA, where higher levels and frequent peaks of
inflammation often occur, primary SS is usually characterized
by chronic but milder inflammation than RA, as our study
confirms [4]. This may justify the lack of correlation between
HDL cholesterol and C-reactive protein [3], also confirmed in our
series (data not shown). Although there are not yet established
criteria of disease activity in SS, anti-SSA/SSB antibodies
represent a disease marker useful to define the diagnosis,
more than the activity of the disease. It has been shown, however,
that these autoantibodies identify younger SS patients at the
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